Prospective studies of resistance guided therapy
Study Design Primary endpoint (ITT)
VIRADAPT G Vs SOC ?VL W12: -1.04 VS -0.46 (diff: 0.58 log)
?VL W12: -1.15 VS -0.67 (diff: 0.48 log)
GART G+EA SOC ?VL W4+8: -1.9 VS 0.61 (diff: 0.85 log)
KAISER P VS SOC ?VL W12: -0.2 log VS -0.4 log
VIRA 3001 P VS SOC % W24: 45% VS 34% (diff: 11%)
NARVAL P VS G VS SOC % W12: 35% VS 44% VS 36%
HAVANA G vs SOC % W24: 49% vs 36% (diff: 13%; pɘ.05)
EA+vs EA- % W24: 47% vs 37% (diff: 10%; p=NS)
ARGENTA G+EA vs SOC+EA % W12: 27% vs 12% (diff: 15%)
CCTG575 P vs SOC %: 48% vs 48%